Pharma BD Deal Intelligence
AstraZeneca's 6-K reports MedImmune's agreement to acquire Definiens AG, a privately held pioneer of Tissue Phenomics imaging and data-analysis technology that…
Fierce Biotech reports MedImmune strengthening its immuno-oncology capabilities through the acquisition of Definiens, whose Cognition Network Technology…
Bahija Jallal (EVP, MedImmune) said Tissue Phenomics will 'accelerate further our clinical programs through its highly precise predictive and prognostic…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
AstraZeneca's MedImmune unit acquired private German digital-pathology firm Definiens for $150M upfront plus undisclosed milestones, gaining the Cognition Network Technology and Tissue Phenomics platform for biomarker-driven companion diagnostics across its immuno-oncology pipeline. Closed November 26, 2014.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Definiens AG (this deal) | 2014 | $150M | 46 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2014 deals · AstraZeneca PLC deals · Oncology deals